Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

Please provide your email address to receive an email when new articles are posted on . An updated guideline on the prevention and management of atrial fibrillation includes a new staging system to ...

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person’s risk of stroke, heart failure and even premature death. While many risk factors contribute to A-fib, one stands ...

Patients with newly diagnosed atrial fibrillation benefit from early rhythm control therapy, according to new results. Patients with newly diagnosed atrial fibrillation benefit from early rhythm ...

The management of patients with atrial fibrillation involves three main areas: anticoagulation, rate control and rhythm control. Importantly, these are not mutually exclusive of each other.

The management of atrial fibrillation (AF) focuses on control of heart rate, correction of rhythm disturbance, prophylaxis of thromboembolism, treatment of underlying disorders, and pathophysiologic ...

Please provide your email address to receive an email when new articles are posted on . A novel SK ion channel inhibitor more often converted atrial fibrillation to sinus rhythm compared with placebo.

A smartphone application (app) can help in screening for atrial fibrillation, according to late breaking results from the DIGITAL-AF study presented today at ESC Congress. A smartphone application ...

In the study of Boriani et al. [13] the median lifetime the percentage of biventricular pacing (BIV%) in the AF group was 95% versus 98% in the entire patient population. When patients with AF were in ...

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers ...